IMVU:LSE:LSE-iShares Edge MSCI Europe Minimum Volatility UCITS ETF EUR (Acc) USD (USD)

ETF | Others |

Last Closing

USD 69.465

Change

+0.41 (+0.59)%

Market Cap

N/A

Volume

557.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

N/A

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 584.80B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 583.82B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

N/A

USD 204.07B
0QZ3:LSE Qualcomm Inc.

N/A

USD 202.26B

ETFs Containing IMVU:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.61% 80% B- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.61% 79% B- 74% C
Trailing 12 Months  
Capital Gain 22.15% 75% C 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.15% 74% C 72% C
Trailing 5 Years  
Capital Gain 35.63% 58% F 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.63% 56% F 63% D
Average Annual (5 Year Horizon)  
Capital Gain 5.77% 53% F 59% D-
Dividend Return 5.77% 53% F 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.00% 50% F 67% D+
Risk Adjusted Return 41.19% 53% F 68% D+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike